专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005097072A1 ION BINDING COMPOSITIONS 审中-公开
标题翻译：离子键合组合物
公开(公告)号：WO2005097072A1
公开(公告)日：2005-10-20
申请号：PCT/US2005/010747
申请日：2005-03-30
申请人： ILYPSA, INC. , CHARMOT, Dominique , FORDTRAN, John , CHANG, Han Ting , CONNOR, Eric , LIU, Mingjun , KLAERNER, Gerrit
发明人： CHARMOT, Dominique , FORDTRAN, John , CHANG, Han Ting , CONNOR, Eric , LIU, Mingjun , KLAERNER, Gerrit
IPC分类号： A61K9/14
CPC分类号： A61K31/78 , A61K9/14 , A61K9/1635 , A61K9/5026 , A61K9/5031 , A61K31/74 , A61K31/785 , A61K31/795 , A61K31/80 , A61K45/06 , C08F120/06 , C08F128/02 , Y10S514/838 , Y10S514/869 , Y10S514/87 , Y10S514/893
摘要： The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
摘要翻译：本发明提供了用于治疗离子失衡的方法和组合物。特别地，本发明提供了核 - 壳组合物及其药物组合物。本文公开了用于治疗和/或预防益处的核 - 壳组合物的使用方法。这些方法的实例包括治疗磷酸盐不平衡障碍，高血压，慢性心力衰竭，终末期肾病，肝硬化，慢性肾功能不全，流体过载或钠过载。

2. 发明申请

WO1993005029A1 TOPICAL OPHTHALMIC IMINO SUBSTITUTED 2-IMINO-3-METHYL-'DELTA'4-1,3,4-THIADIAZOLINE-5-SULFONAMIDES CARBONIC ANHYDRASE INHIBITORS 审中-公开
标题翻译：取代的2-氨基-3-甲基-3,3-1,3-二氮杂环丁烷-5-磺酰胺碳酸酐酶抑制剂的局部OPHTHALMIC IMINO
公开(公告)号：WO1993005029A1
公开(公告)日：1993-03-18
申请号：PCT/US1991009364
申请日：1991-12-13
申请人： UNIVERSITY OF IOWA RESEARCH FOUNDATION
发明人： UNIVERSITY OF IOWA RESEARCH FOUNDATION , SCHOENWALD, Ronald, D. , BARFKNECHT, Charles, F.
IPC分类号： C07D285/12
CPC分类号： C07D285/135 , C07D277/80 , C07D417/12 , C07H15/18 , C07H15/203 , C07H15/26 , C07H17/00 , Y10S514/869 , Y10S514/913
摘要： High potency carbonic anhydrase inhibitors derived from methazolamide.
摘要翻译：来自甲唑胺的高效碳酸酐酶抑制剂。

3. 发明申请

WO02040007A1 SYNERGISTIC COMBINATIONS COMPRISING A RENIN INHIBITOR FOR CARDIOVASCULAR DISEASES 审中-公开
标题翻译：包含用于心血管疾病的瑞宁抑制剂的协同组合
公开(公告)号：WO02040007A1
公开(公告)日：2002-05-23
申请号：PCT/EP2001/013241
申请日：2001-11-15
IPC分类号： A61K45/00 , A61K31/165 , A61K31/405 , A61K31/41 , A61K31/437 , A61K31/4422 , A61K31/47 , A61K31/506 , A61K31/549 , A61K31/55 , A61K31/554 , A61K31/585 , A61K31/64 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/06 , A61P7/10 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P13/12 , A61P19/04 , A61P27/06 , A61P43/00
CPC分类号： A61K45/06 , A61K31/165 , A61K31/451 , A61K31/542 , Y10S514/869 , Y10S514/929 , A61K2300/00
摘要： The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及包含式（I）的肾素抑制剂或其药学上可接受的盐的组合。

4. 发明申请

WO1979001037A1 1-HYDROXYALKANAMINE PYRANO(3,4-B)INDOLE DERIVATIVES 审中-公开
标题翻译： 1-羟基烷胺吡咯烷（3,4-B）吲哚衍生物
公开(公告)号：WO1979001037A1
公开(公告)日：1979-11-29
申请号：PCT/US1979000256
申请日：1979-04-19
申请人： AMERICAN HOME PROD CORP
发明人： AMERICAN HOME PROD CORP , ASSELIN A , FAILLI A , DIONNE G , REVESZ C , HUMBER L
IPC分类号： A61K31/40
CPC分类号： C07D491/04 , C07D495/04 , Y10S514/869
摘要： New compounds of formula I (FORMULA) in which R1 is lower alkyl; R2 is hydrogen or lower alkyl; R3 and R4 each independently is hydrogen, lower alkyl halo, nitro, trifluoromethyl or lower alkoxy; R5 and R6 each independently is hydrogen or lower alkyl or R5 and R6 together with the nitrogen atom form a pyrrol-1-yl, piperidino or morpholino ring; R7 is hydrogen or lower alkyl; Alk1 and Alk2 each independently is a straight or branched chain lower alkylene having one to six carbon atoms; and X is oxa or thia, and therapeutically acceptable acid addition salts thereof. The above compounds are diuretic agents, which also possess anti-hypertensive activity. They may be used alone or with other diuretic agents. Pharmaceutical compositions containing the compounds and processes for preparing the compounds are also described.

5. 发明申请

WO2006001931A2 PROUROGUANYLIN, AND SYNTHETIC ANALOGS OR PROTEOLYTIC CLEAVAGE PRODUCTS DERIVED FROM IT, AS THERAPEUTIC AND DIAGNOSTIC AGENTS FOR DISEASES INVOLVING SALT AND/OR FLUID HOMEOSTASIS 审中-公开
标题翻译： PROUROGUANYLIN，以及衍生自其的合成类似物或蛋白质清除产品，作为涉及盐和/或液体家庭病的疾病的治疗和诊断代理
公开(公告)号：WO2006001931A2
公开(公告)日：2006-01-05
申请号：PCT/US2005016937
申请日：2005-05-16
申请人： UNIV NORTH CAROLINA , GOY MICHAEL F , MOOS NICHOLAS G , QIAN XUN
发明人： GOY MICHAEL F , MOOS NICHOLAS G , QIAN XUN
IPC分类号： A61K38/22
CPC分类号： A61K38/1709 , Y10S514/869 , A61K2300/00
摘要： A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized by salt retention, fluid retention, salt loss, fluid loss, and combinations thereof. An immunoassay kit for detecting a level of prouroguanylin in a sample.
摘要翻译：一种治疗以盐保留，液体保留及其组合为特征的病症的方法。用于确定以盐保留，液体保留，盐损失，液体流失及其组合为特征的病症的存在或进展的方法。用于检测样品中prouroguanylin水平的免疫测定试剂盒。

6. 发明申请

WO00027383A1 DYSURIA REMEDIES 审中-公开
标题翻译： DYSURIA救济
公开(公告)号：WO00027383A1
公开(公告)日：2000-05-18
申请号：PCT/JP1999/006170
申请日：1999-11-05
IPC分类号： A61K31/167 , A61K45/06 , A61P13/08 , A61P13/10 , A61P35/00
CPC分类号： A61K45/06 , A61K31/167 , Y10S514/826 , Y10S514/869 , Y10S514/968 , A61K2300/00
摘要： Remedies for dysuria and lower urinary tract diseases, containing as the active ingredient [2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]-ethyl]dimethylsulfonium salts of organic acids. These remedies enable the treatment of lower urinary tract diseases causative of dysuria, e.g., interstitial cystitis and prostatitis which have not yet been elucidated in the cause and have been believed to be intractable.
摘要翻译：含有作为活性成分[2- [4-（3-乙氧基-2-羟基丙氧基）苯基氨基甲酰基] - 乙基]二甲基锍盐的排尿困难和下尿路疾病的补救措施。这些治疗方法能够治疗导致排尿困难的下尿路疾病，例如间质性膀胱炎和前列腺炎，其原因尚未阐明，并被认为是难治性的。

7. 发明申请

WO1984003623A1 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：WO1984003623A1
公开(公告)日：1984-09-27
申请号：PCT/GB1984000099
申请日：1984-03-26
申请人： BLOCH, Maurice
IPC分类号： A61K09/22
CPC分类号： A61K9/5078 , A61K33/06 , A61K33/08 , Y10S514/819 , Y10S514/869
摘要： A pharmaceutical composition comprises magnesium oxide, hydroxide or a non-toxic salt of magnesium in a slow-release carrier; this material may be combined with or co-prescribed with a diuretic or cardiac glycoside or adrenergic receptor blocking agent or a calcium antagonist for the treatment of hypertension or angina pectoris.
摘要翻译：药物组合物包含缓释载体中的氧化镁，氢氧化物或镁的无毒盐; 该物质可以与用于治疗高血压或心绞痛的利尿剂或强心苷或肾上腺素能受体阻断剂或钙拮抗剂组合或共同施用。

8. 发明申请

WO1995020579A1 CYANOGUANIDINES AS K-CHANNEL BLOCKERS 审中-公开
标题翻译： CYANOGUANIDINES作为K-通道阻塞剂
公开(公告)号：WO1995020579A1
公开(公告)日：1995-08-03
申请号：PCT/US1995000024
申请日：1995-01-09
申请人： THE UPJOHN COMPANY , HUMPHREY, Stephen, J. , MEISHERI, Kaushik, D. , LUDENS, James, H. , HESTER, Jackson, B., Jr.
发明人： THE UPJOHN COMPANY
IPC分类号： C07D213/75
CPC分类号： C07D213/75 , Y10S514/869
摘要： Cyanoguanidine compounds of Formula (I) and their pharmaceutically acceptable acid addition salts where R1 is hydrogen or methyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl C3-C5 cycloalkyl, C3-C5 cycloalkenyl, hydroxymethyl, methoxy C1-C5 alkyl, or R1 and R2 are combined to form a C3-C6 carboxyclic ring; R3 and R4 are each independently selected to be hydrogen, C1-C4 alkyl, F, Cl, Br, I or CF3; R5 is hydrogen, F or Cl; R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)mOC1-C3 alkyl, NHC(O)C1-C3 alkyl, F, Cl, Br, C1-C3 alkyl, NH(CH2)mF, 1-imidazolyl, NHOC1-C3 alkyl, NHOH, NHSO2C1-C3 alkyl, SH, SC1-C3 alkyl, NHC(O)OC1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2 or amino acid amide; R7 is C1-C7 alkyl, NH2, NHC1-C3 alkyl, N(C1-C3 alkyl)2, CF3, F, Cl, Br, I, OC1-C3 alkyl, OH, COOH, C(O)OC1-C3 alkyl, C(O)NH2, C(O)NHC1-C3 alkyl, C(O)C1-C3 alkyl, C(O)N(C1-C3 alkyl)2, SO2NH2, SO2NHC1-C3 alkyl, CN, SO2N(C1-C3 alkyl)2, NHC(O)C1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHC(O)N(C1-C3 alkyl)2, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2, SH, SC1-C3 alkyl, NO2, SO2C1-C3 alkyl, NHC(O)OC1-C3 alkyl, amino acid amide or hydrogen; R8 is hydrogen, C1-C6 alkyl, NH2, NHC1-C3 alkyl, N(CH3)2, N(C2H5)2, F, Cl, Br, OC1-C3 alkyl or OH; and where m is 2 or 3 and n is 0 or 1 (except for those compounds where R8 is hydrogen and R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)m-OC1-C3 alkyl, NHC(O)C1-C3 alkyl, Cl or Br). The compounds of Formula (I) are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.
摘要翻译：式（I）的氰基胍化合物及其药学上可接受的酸加成盐，其中R 1是氢或甲基; R 2是C 1 -C 6烷基，C 2 -C 6烯基，C 2 -C 6炔基C 3 -C 5环烷基，C 3 -C 5环烯基，羟甲基，甲氧基C 1 -C 5烷基或R 1和R 2结合形成C 3 -C 6羧基环; R 3和R 4各自独立地选自氢，C 1 -C 4烷基，F，Cl，Br，I或CF 3; R5是氢，F或Cl; R6是氢，NH2，NHCH3，NHC2H5，NHCH（CH3）2，N（CH3）2，N（C2H5）2，NH（CH2）mOC1-C3烷基，NHC（O）C1-C3烷基， Br，C1-C3烷基，NH（CH2）mF，1-咪唑基，NHOC1-C3烷基，NHOH，NHSO2C1-C3烷基，SH，SC1-C3烷基，NHC（O）OC1-C3烷基，NHC（O） -C 3烷基，NHSO 2 NHC 1 -C 3烷基，NHSO 2 N（C 1 -C 3烷基）2或氨基酸酰胺; R 7是C 1 -C 7烷基，NH 2，NHC 1 -C 3烷基，N（C 1 -C 3烷基）2，CF 3，F，Cl，Br，I，OC 1 -C 3烷基，OH，COOH，C（O），C（O）NH2，C（O）NHCl-C3烷基，C（O）C1-C3烷基，C（O）N（C1-C3烷基）2，SO2NH2，SO2NHC1-C3烷基，CN，SO2N C 1 -C 3烷基）2，NHC（O）C 1 -C 3烷基，NHC（O）NHCl 3 C 3烷基，NHC（O）N（C 1 -C 3烷基）2，NHSO 2 NHC 1 -C 3烷基，NHSO 2 N ，SH，SC1-C3烷基，NO2，SO2C1-C3烷基，NHC（O）OC1-C3烷基，氨基酰胺或氢; R 8是氢，C 1 -C 6烷基，NH 2，NHCl-C 3烷基，N（CH 3）2，N（C 2 H 5）2，F，Cl，Br，OC 1 -C 3烷基或OH; 并且其中m为2或3且n为0或1（除了那些其中R 8为氢且R 6为氢，NH 2，NHCH 3，NHC 2 H 5，NHCH（CH 3）2，N（CH 3）2，N（C 2 H 5）2 ，NH（CH 2）m -OC 1 -C 3烷基，NHC（O）C 1 -C 3烷基，Cl或Br）。式（I）的化合物是可用于治疗心血管疾病如充血性心力衰竭和高血压以及作为利尿剂的钾通道阻滞剂。

9. 发明申请

WO1994005286A1 READY-TO-INJECT AZOSEMIDE SOLUTIONS 审中-公开
标题翻译： SPRAY READY阿佐塞米注射液，
公开(公告)号：WO1994005286A1
公开(公告)日：1994-03-17
申请号：PCT/EP1993002331
申请日：1993-08-28
申请人： BOEHRINGER MANNHEIM GMBH , WOOG, Heinrich , GRUBER, Werner
发明人： BOEHRINGER MANNHEIM GMBH
IPC分类号： A61K31/41
CPC分类号： A61K47/18 , A61K9/0019 , A61K31/635 , A61K47/02 , A61K47/26 , Y10S514/869
摘要： The invention concerns a ready-to-inject aqueous solution of a water-soluble, physiologically tolerated azosemide salt of an organic amide, the solution containing an organic solvent and optionally a physiologically tolerated buffer. The invention also concerns a method of preparing such an injection solution, the method calling for the salt to be dissolved in a mixture containing water, an organic solvent and optionally a physiologically tolerated buffer.

10. 发明申请

WO1991010142A1 DETERMINING THE DIURETIC POTENCY OF CANDIDATE DRUGS 审中-公开
标题翻译：确定候选药物的滴度
公开(公告)号：WO1991010142A1
公开(公告)日：1991-07-11
申请号：PCT/US1990007700
申请日：1990-12-31
申请人： CHILDREN'S MEDICAL CENTER CORPORATION
发明人： CHILDREN'S MEDICAL CENTER CORPORATION , HARRIS, H., William , ZEIDEL, Mark, L.
IPC分类号： G01N33/94
CPC分类号： G01N33/5436 , G01N33/5008 , G01N33/743 , Y10S514/836 , Y10S514/869
摘要： A method for determining the diuretic potency of candidate drugs as inhibitors of ADH-elicited water channels is disclosed. In a preferred embodiment, such diuretic potency of candidate drugs is determined by suspending vesicles containing ADH water channels in an aqueous suspending medium, incorporating the candidate into the suspension, rapidly changing the pH of the suspending medium and thereafter detecting the proton permeability of the water channels. The proton permeability in the presence of the candidate drug can then be compared to the proton permeability of water channels under similar conditions without the presence of the candidate drug to determine the diuretic potency of the candidate drug to inhibit ADH-elicited water channels.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式